MedEnrich | Página principal
Continue Watching
últimos vidéos
últimos vidéos
Brightcove Home Latest Listing
Cáncer de mama
Cáncer de mama
Brightcove Cards Listing
Cáncer de próstata
Brightcove Cards Listing
Mieloma múltiple
Mieloma múltiple
Brightcove Cards Listing
Popular en MedEnrich
Popular in Sin nombre
Cáncer de mama3m 36s
Tumor Infiltrating Lymphocytes as Predictive Biomarker in Breast Cancer
Immune cells known as tumor-infiltrating lymphocytes (TILs) are thought to be a promising, affordable biomarker with prognostic and predictive potential.
tumor-infiltrating lymphocytes (tils)
promising biomarker
1
Tumor Infiltrating Lymphocytes as Predictive...
Cáncer de mama29m 30s
SABCS Update 2022
Summary of Key Abstracts from SABCS 2022
recurrence score
tailor-x
destiny breast 03
adjuvant cdk4/6 inhibitor
antibody drug conjugates
1
SABCS Update 2022
Cáncer de mama8m 55s
Understanding HER-2 Low Breast Cancer Entity & Treatment Strategy
Tumors with a HER-2 immunohistochemistry (IHC) score of 1 + or 2 + and a negative molecular reflex test have been classified as HER2-low Breast Cancers.
trastuzumab-deruxtecan (t-dxd)
her2 low breast cancers
1
Understanding HER-2 Low Breast Cancer Entity &...
Cancer de prostata11m 38s
Treatment Intensification in Metastatic Castration Sensitive Prostate Cancer
PEACE-1 clinical trial demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone (AAP) improves both overall survival (OS) and radiographic progression-free-survival (rPFS) in men with de novo mCSPC.
treatment intensification
mhspc
triplet therapy
peace-1 clinical trial
1
Treatment Intensification in Metastatic Castration...
Cáncer de mama8m 46s
Expert Perspective - How I Treat Metastatic Her2 Positive Breast Cancer
Anti-HER2 directed therapy remains the cornerstone of care for individuals with HER2-positive metastatic breast cancer (MBC).
anti-her2 directed therapy
her2-positive metastatic breast cancer
expert perspective
algorithm for management of her2 positive mbc
1
Expert Perspective - How I Treat Metastatic Her2...
Mieloma múltiple7m 42s
MRD Assesment in Multiple Myeloma -Ready for Prime Time
Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.
minimum residual disease (mrd)
mrd negativity
multiple myeloma
1
MRD Assesment in Multiple Myeloma -Ready for Prime...
Oncology1m 36s
Enhancing Global Access to Cancer Medicines
Over the last decade we have seen emergence of increasing novel therapies like targeted therapy and immunotherapy & this has changed the natural history of disease for patients living with cancer including those with advanced disease.
biosimilars
access
generics
1
Enhancing Global Access to Cancer Medicines
Mieloma múltiple13m 11s
Management of Infections in Multiple Myeloma
Risk of infections in multiple myeloma has increased with the use of Novel treatments like Proteosome inhibitors, CD38 targeting MABs & BCMA targeted drugs.
prophylaxis
infections
vaccination
myeloma
1
Management of Infections in Multiple Myeloma
Oncology13m 52s
Guidelines for Treatment of Diffuse Gliomas
Classification & treatment of Gliomas have evolved from erstwhile histopathology based to recent one incorporating molecular markers.
glioma
guidelines
idh mutations
1
Guidelines for Treatment of Diffuse Gliomas
Cancer de prostata6m 59s
Managing Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
3 randomized clinical trials (SPRATAN- Apalutamide), (PROSPER -Enzalutamide) & (ARAMIS -Darolutamide) have shown consistent and almost similar benefit in Metastasis Free Survival in nmCRPC
nmcrpc
metastasis free survival
spartan
prosper & aramis clinical trial
1
Managing Nonmetastatic Castration-Resistant...
Seminarios web anteriores
Seminarios web anteriores
Webinar Cards Listing
Artículos
Artículos
Medbytes Cards Listing
Iniciar sesión
Por favor inicie sesión para acceder a todo el contenido de MedEnrich
¿Es nuevo/a en MedEnrich? Regístrese ahora